What's Ahead For This Dividend Darling: Bristol-Myers Squibb Company (NYSE:BMY)

Marco Green
April 17, 2018

As a company's earnings per share being to rise, so does their market value per share. Sabby Management Llc who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $95.89B market cap company. The stock decreased 8.22% or $4.8207 during the last trading session, reaching $53.8293. About 537,773 shares traded. The third largest holder is Blackrock Inc., which now holds $6.14 billion worth of this stock and that ownership represents almost 6.25% of its market capitalization. It has underperformed by 0.18% the S&P500.

Hillman Co increased its stake in Facebook Inc (FB) by 1.18% based on its latest 2017Q4 regulatory filing with the SEC. Other ratios are PEG, which now sits at 2.1 and Price to Cash sits at 14.12. At the end of 2017Q4, the 175,000 shares of the major pharmaceuticals company held by the institutional investor were valued at $10.72M, up from 60,000 at the end of the previous reported quarter.

Captrust Financial Advisors acquired a new position in Bristol-Myers Squibb (NYSE:BMY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The stock decreased 0.34% or $0.27 during the last trading session, reaching $79.57. Farr Miller Washington Limited Com Dc holds 380,008 shares or 2.08% of its portfolio. AT&T Inc. (NYSE:T) has declined 15.88% since April 16, 2017 and is downtrending. It has underperformed by 11.95% the S&P500.

Investors sentiment increased to 1.4 in 2017 Q4. That's change of 0.09, from 2017Q3's 1.03. If the investor already owns shares of the stock, he should hold onto the equity and see how it performs over the short-, medium- and long-term. 457 grew positions while 106 funds amassed positions. The Loomis Sayles & Company LP holds 13.51 million shares with $828.12 million value, down from 13.59 million last quarter.

Merck rose 2.29 percent after the company presented positive data on its cancer drug Keytruda, driving a 0.7 percent gain in the healthcare index. Jefferies Group set a $72.00 price objective on Bristol-Myers Squibb and gave the company a "hold" rating in a research note on Monday, February 26th. DZ Bank downgraded Bristol-Myers Squibb Company (NYSE:BMY) on Wednesday, February 28 to "Hold" rating. Btr Cap Mgmt has invested 0.06% in Bristol-Myers Squibb Company (NYSE:BMY). 229.56 million shares or 8.37% less from 250.53 million shares in 2017Q3 were reported. Alabama-based Retirement Of Alabama has invested 0.23% in Bristol-Myers Squibb Company (NYSE:BMY). Regions Corp holds 0.43% or 223,813 shares. River Mercantile Asset Management Limited Liability Partnership has 0.38% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 55,600 shares. For the Current month, 5 analysts have assigned this stock as Buy where 4 assigned Outperform, 11 analysts believe it's a Hold, 2 said Underperform and only 1 assigned Sell rating. Therefore 91% are positive. Eagleclaw Managment Limited Liability Company has 0.32% invested in Bristol-Myers Squibb Company (NYSE:BMY). The firm has "Hold" rating given on Monday, February 5 by Mizuho. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has "Hold" rating given on Thursday, July 14 by Jefferies. Citigroup maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Wednesday, October 25. The company was maintained on Monday, March 5 by Bank of America. The rating was initiated by Mizuho on Tuesday, April 19 with "Buy".

Since December 12, 2017, it had 1 buy, and 1 insider sale for $85,985 activity. The company's shares were given away at $63.24 per share worth to an income of some $335,172 on account of Lynch Thomas J. Jr.

Sabby Management Llc, which manages about $835.79 million and $1.10 billion US Long portfolio, upped its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 58,828 shares to 142,185 shares, valued at $9.36 million in 2017Q4, according to the filing. This represents a $1.60 annualized dividend and a dividend yield of 2.73%. If we take an observation in front to the next coming days, Street analysts have hope earnings growth of 18.90% for this year and may be getting earnings growth of 17.86% for next year. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market.

The company's Average Earnings Estimate for the Current Fiscal quarter is $1.23, according to consensus of 18 analysts. DBD's profit will be $759,129 for 373.13 P/E if the $0.01 EPS becomes a reality. Another trade for 16,000 shares valued at $2.83 million was sold by Cox Christopher K. On Friday, December 15 the insider Riker Lauren Bullaro sold $14,858.

As of now, Bristol-Myers Squibb Company has a P/S, P/E and P/B values of 4.72, 24.87 and 8.17 respectively.

Investors sentiment decreased to 1.02 in Q4 2017. It fall, as 40 investors sold CF shares while 158 reduced holdings. 147 funds opened positions while 670 raised stakes. Cypress Mngmt Limited Liability reported 6,450 shares stake. Vident Investment Advisory Ltd invested in 21,254 shares. British Columbia Invest Management Corporation accumulated 969,308 shares. Richard Bernstein Advsr Ltd has 0.81% invested in Facebook, Inc. Benedict Fincl Advsrs accumulated 16,751 shares. (NASDAQ:PCRX). Westfield Capital Mgmt LP holds 1.25 million shares. (NASDAQ:FB) for 276,403 shares. Glenmede Trust Company Na reported 0% in Pinnacle Financial Partners, Inc. (NYSE:T). Mcdaniel Terry And reported 0.09% in AT&T Inc. Park Presidio Capital Llc owns 1.80 million shares or 4.56% of their United States portfolio.

Other reports by Click Lancashire

Discuss This Article